<DOC>
	<DOC>NCT01046487</DOC>
	<brief_summary>The purpose of this study is to determine the maximum tolerated dose of imatinib mesylate, given in association with a fixed dose of cyclophosphamide (50 mg bid).</brief_summary>
	<brief_title>Imatinib Mesylate And Cyclophosphamide In Metronomic Administration: Dose Escalation Study Of Imatinib Mesylate</brief_title>
	<detailed_description />
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>Rare tumor metastatic disease or locally advanced disease, inoperable, with no standard treatment At least 28 days since the prior treatment Measurable disease with at least one measurable lesion Medullary insufficiency Cystitis, haemorrhagic cystitis Hepatic porphyria</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>dermatofibrosarcoma</keyword>
	<keyword>cylindroma</keyword>
	<keyword>choroid melanoma</keyword>
	<keyword>gastrointestinal stroma tumor</keyword>
	<keyword>chordoma</keyword>
	<keyword>ocular melanoma</keyword>
	<keyword>conjunctival melanoma</keyword>
	<keyword>malignant melanoma of the anus</keyword>
	<keyword>gastric melanoma</keyword>
	<keyword>desmoid tumor</keyword>
</DOC>